Fig. 5: Synergistic effects with BQ are specific to BCL-XL inhibition in PDAC.
From: De novo pyrimidine biosynthesis inhibition synergizes with BCL-XL targeting in pancreatic cancer
a–f Percentage cell viability of PaTu-8902 and PaTu-8988T cells after treatment with increasing concentrations of BQ with DT2216 (BCL-XL PROTAC), AZD-5991 (MCL1 inhibition) or Venetoclax (BCL2 inhibition) for 5 days. IC50 values are shown for a representative experiment out of three independent experiments. Error bars represent s.d. of two-three technical replicates (two technical replicates for BQ alone conditions). g, h Clonogenic growth of PaTu-8902 and PaTu-8988T cells treated with BQ (5 µM), DT2216 (5 µM), Venetoclax (5 µM), AZD-5991 (5 µM) or DT2216, Venetoclax or AZD-5991 in combination with BQ. Data are shown as mean values with error bars representing the s.d. of average of three independent experiments (each in three technical replicates). Significance was determined with t test (unpaired, two-tailed). *p  <  0.05, ****p  <  0.0001. Source data are provided as a Source Data file.
